New drug aims to tame inflammation in kidney patients
NCT ID NCT04626505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug, ziltivekimab, in 36 adults with advanced chronic kidney disease (not on dialysis) to see if it can safely reduce inflammation and related heart risks. Participants received either a low dose, a high dose, or a placebo injection every 4 weeks for 3 doses. The main goal was to measure changes in a blood marker of inflammation (hs-CRP) over 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ehime Medical Center
Ehime, 791-0281, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could a gentle yoga practice turn down the Body's pain and inflammation?
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Could your gut bacteria hold the key to protecting your kidneys?
- Grape powder may help aging immune systems — a trial puts it to the test
- Food as medicine: could cooking classes slow kidney disease?